-Study participant must have a diagnosis of moderate to severe plaque psoriasis (PSO) for ≥3 months and: 1. Body Surface Area (BSA) affected by psoriasis ≥10 % 2. Physician’s Global Assessment (PGA) score ≥3 (on a scale from 0 to 4) 3. Psoriasis Area and Severity Index (PASI) score is ≥12 or 4. PASI score is ≥10 and <12 with at least one of the following: ->Clinically relevant facial or scalp involvement ->Clinically relevant genital involvement ->Clinically relevant palm and sole involvement ->Clinically relevant axillary involvement Study participants aged ≥12 years may alternatively have a diagnosis of moderate to severe mixed guttate/plaque PSO with >50 % to <80 % guttate lesions for ≥3 months, and must meet the same criteria listed above -Study participant must be a candidate for systemic psoriasis therapy and/or phototherapy and/or photochemotherapy